mmbu

โครงการวิจัยที่หน่วยวิจัยคลินิกให้บริการ ซึ่งอยู่ในระหว่างดำเนินการ

  • Effectiveness and Efficiency of Ertapenem for Treatment of ESBL Producing Gram-Negative Bacterial Infections.
  • Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity.
  • Real-Time Polymerase Chain Reaction for Rapid Detection of Candida Species in Blood Samples.
  • Epidemiology of Cause of Fever in Postneurosurgical Patients in Siriraj Hostpital.
  • A Long-Term, Open-Label Follow-up Study of Tasocitinib (CP-690,500) for Treatment of Rheumatoid Arthritis.
  • Prospective Study of Clinical Characteristics, Outcome and Course of Disease in Patients with Spondyloarthritis in Siriraj Hospital.
  • A Phase I, Open-Label, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults with Hematologic Malignancies Receiving Treatment with Anti-CD20 Monoclonal Antibodies.
  • A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy.
  • A Phase III International, Randomized, Double-Blind, Double–Dummy Study to Evaluate the Efficacy and Safety of 300 mg Or 600 mg of Intravenous Zanamivir Twice Daily Compare to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents with Influenza.
  • Estimation of the Optimal Treatment Duration and Cumulative Dose of BP-C1 in Breast Cancer Patients with Distant Metastases: A Phase IC Dose-Response Study.
  • A Randomized, Double Blind and Placebo Controlled Multicentre Study Comparing BP-C1 and Equal Looking Placebo in Metastatic Breast Cancer Patients. A Phase IIB Study.
  • A Multicenter, Double-Blind, Double-Dummy Randomized, Positive-Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 To 600mg/Day) to Controlled Release Carbamazepine (400 to 1,200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed with Epilepsy and Experiencing Partial-Onset or Generalized Tonic-Clonic Seizures(SP0993 Study).
  • A Multicenter, Double–Blind, Double–Dummy Follow–up Study Evaluating the Long–Term Safety of Lacosamide (200 to 600 mg/Day) in Comparison with Carbamazepine (400 to 1,200 mg/ Day), Used as Monotherapy in Subjects with Partial–Onset or Generalized Tonic–Clinic Seizures (≥16 Years) of Age Coming from the SP0993 Study (SP0994 Study).
  • The Asia Cornea Society Infectious Keratitis Study (ACSIKS).
  • Evaluation of Efficacy and Health-Economic Effect of Preoperative Skin Preparation between Duraprep and Conventional Method to Prevent Surgical Site Infection in Abdominal Surgery.
  • A Phase III, Randomized, Multicenter, Double-Blind, Double-Dummy,Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime/Avibactam (CAZ104) Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections (cIAIs) in Hospitalized Adults
  • A Phase II, Randomized, Observer-Blind with Single-Blind Booster, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two_V89_13 Different Formulations in Healthy Elderly Subjects.
  • A Multi-Center, Phase IV, Randomized, Controlled, Observer Blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Trivalent Subunit Inactivated Influenza Vaccine in Healthy Subjects Aged 50 Years and Above.
  • Effectiveness and Safety of GRACEVITTM for Therapy of Bacterial Urinary Tract Infections.
  • Microbiological Activity Against ESBL Enzymes Producing E.Coli of Serum Samples and Urine Samples of Healthy Subjects after Receiving Oral Antibiotics Active Against ESBL Enzymes Producing E.Coli
  • A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, A Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women.
หน่วยวิจัยคลินิก สถานส่งเสริมการวิจัย คณะแพทยศาสตร์ศิริราชพยาบาล อาคารเฉลิมพระเกียรติ ๘๐ พรรษา ๕ ธันวาคม ๒๕๕๐ (ศูนย์วิจัยการแพทย์ศิริราช, SiMR) ชั้น 3 ห้อง 307 2 ถนนพรานนก แขวงศิริราช เขตบางกอกน้อย กรุงเทพฯ 10700 โทรศัพท์ 0 2419 2703 โทรสาร 0 2418 1107 E-mail: sirect@mahidol.ac.th